Changes in self-reactive IgG antibody repertoire after treatment of experimental autoimmune encephalomyelitis with anti-allergic drugs

Journal of Neuroimmunology

Volumn 182, Issue 1-2, 2007, Pages 80-88

  El Behi, Mohamed ^a   Zéphir, Hélène ^b   Lefranc, Didier ^a   Dutoit, Virginie ^a   Dussart, Patricia ^a   Devos, Patrick ^b   Dessaint, Jean Paul ^a   Vermersch, Patrick ^b   Prin, Lionel ^a  

^a UNIV LILLE   (France)

^b LILLE UNIVERSITY HOSPITAL   (France)

Author keywords

Allergy; EAE; Proteomic; Self antigens

Indexed keywords

2 [N (2 METHOXY 3 OCTADECYLCARBAMOYLOXYPROPOXYCARBONYL)ACETAMIDOMETHYL] 1 ETHYLPYRIDINIUM CHLORIDE; ANTIALLERGIC AGENT; HISTAMINE; HISTAMINE H1 RECEPTOR ANTAGONIST; IMMUNOGLOBULIN G ANTIBODY; INTERMEDIATE FILAMENT PROTEIN; INTERNEXIN; MALATE DEHYDROGENASE; MALATE DEHYDROGENASE 1; MEPYRAMINE; THROMBOCYTE ACTIVATING FACTOR; THROMBOCYTE ACTIVATING FACTOR ANTAGONIST; UNCLASSIFIED DRUG;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN HOMOGENATE; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; FEMALE; IMMUNE RESPONSE; IMMUNOGLOBULIN BLOOD LEVEL; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MOUSE; NEUROPROTECTION; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; TREATMENT OUTCOME; TWO DIMENSIONAL ELECTROPHORESIS;

ANIMALS; ANTI-ALLERGIC AGENTS; ANTIBODIES, ANTI-IDIOTYPIC; CENTRAL NERVOUS SYSTEM; ELECTROPHORESIS; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; FEMALE; HISTAMINE ANTAGONISTS; HISTAMINE H1 ANTAGONISTS; IMMUNOBLOTTING; IMMUNOGLOBULIN G; INTERMEDIATE FILAMENT PROTEINS; MALATE DEHYDROGENASE; MICE; MICE, INBRED STRAINS; PLATELET ACTIVATING FACTOR; PLATELET MEMBRANE GLYCOPROTEINS; PROTEOMICS; PYRIDINIUM COMPOUNDS; PYRILAMINE; RECEPTORS, G-PROTEIN-COUPLED; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION;

EID: 33845998240     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2006.10.002     Document Type: Article

References (57)

1. Almeras L., Lefranc D., Drobecq H., De Seze J., Dubucquoi S., Vermersch P., and Prin L. New antigenic candidates in multiple sclerosis: identification by serological proteome analysis. Proteomics 4 (2004) 2184-2194
2. Alonso A., Jick S.S., and Hernan M.A. Allergy, histamine 1 receptor blockers, and the risk of multiple sclerosis. Neurology 66 (2006) 572-575
3. Archelos J.J., Storch M.K., and Hartung H.P. The role of B cells and autoantibodies in multiple sclerosis. Ann. Neurol. 47 (2000) 694-706
4. Banu Y., and Watanabe T. Augmentation of antigen receptor-mediated responses by histamine H1 receptor signaling. J. Exp. Med. 189 (1999) 673-682
5. Baranzini S.E., Jeong M.C., Butunoi C., Murray R.S., Bernard C.C., and Oksenberg J.R. B cell repertoire diversity and clonal expansion in multiple sclerosis brain lesions. J. Immunol. 163 (1999) 5133-5144
6. Baranzini S.E., Bernard C.C., and Oksenberg J.R. Modular transcriptional activity characterizes the initiation and progression of autoimmune encephalomyelitis. J. Immunol. 174 (2005) 7412-7422
7. Bebo Jr. B.F., Yong T., Orr E.L., and Linthicum D.S. Hypothesis: a possible role for mast cells and their inflammatory mediators in the pathogenesis of autoimmune encephalomyelitis. J. Neurosci. Res. 45 (1996) 340-348
8. Brenner T., Soffer D., Shalit M., and Levi-Schaffer F. Mast cells in experimental allergic encephalomyelitis: characterization, distribution in the CNS and in vitro activation by myelin basic protein and neuropeptides. J. Neurol. Sci. 122 (1994) 210-213
9. Brochet B., Guinot P., Orgogozo J.M., Confavreux C., Rumbach L., and Lavergne V. Double blind placebo controlled multicentre study of ginkgolide B in treatment of acute exacerbations of multiple sclerosis. The Ginkgolide Study Group in multiple sclerosis. J. Neurol. Neurosurg. Psychiatry 58 (1995) 360-362
10. Bubber P., Haroutunian V., Fisch G., Blass J.P., and Gibson G.E. Mitochondrial abnormalities in Alzheimer brain: mechanistic implications. Ann. Neurol. 57 (2005) 695-703
11. Callea L., Arese M., Orlandini A., Bargnani C., Priori A., and Bussolino F. Platelet activating factor is elevated in cerebral spinal fluid and plasma of patients with relapsing-remitting multiple sclerosis. J. Neuroimmunol. 94 (1999) 212-221
12. Colombo M., Dono M., Gazzola P., Roncella S., Valetto A., Chiorazzi N., Mancardi G.L., and Ferrarini M. Accumulation of clonally related B lymphocytes in the cerebrospinal fluid of multiple sclerosis patients. J. Immunol. 164 (2000) 2782-2789
13. Cross A.H., Trotter J.L., and Lyons J. B cells and antibodies in CNS demyelinating disease. J. Neuroimmunol. 112 (2001) 1-14
14. Finkelman F.D., Rothenberg M.E., Brandt E.B., Morris S.C., and Strait R.T. Molecular mechanisms of anaphylaxis: lessons from studies with murine models. J. Allergy Clin. Immunol. 115 (2005) 449-457
15. Fujitani T., Adachi N., Nagaro T., Miyazaki H., Nakamura Y., Kataoka K., and Arai T. Histaminergic H2 action protects hippocampal CA1 neurons by prolonging the onset of the anoxic depolarization in gerbils. J. Neurochem. 67 (1996) 2613-2615
16. Genain C.P., Cannella B., Hauser S.L., and Raine C.S. Identification of autoantibodies associated with myelin damage in multiple sclerosis. Nat. Med. 5 (1999) 170-175
17. Jutel M., Watanabe T., Klunker S., Beccel Akdis M., Thornet O.A.R., Malolepszy J., Zak-Nejmark T., Koga R., Kobayashi T., Blaser K., and Akdis C.A. Histamine regulates T-cell and antibody responses by differential expression of H1 and H2 receptors. Nature 413 (2001) 420
18. Kihara Y., Ishii S., Kita Y., Toda A., Shimada A., and Shimizu T. Dual phase regulation of experimental allergic encephalomyelitis by platelet-activating factor. J. Exp. Med. 202 (2005) 853-863
19. Kuchroo V.K., Anderson A.C., Waldner H., Munder M., Bettelli E., and Nicholson L.B. T cell response in experimental autoimmune encephalomyelitis (EAE): role of self and cross-reactive antigens in shaping, tuning, and regulating the autopathogenic T cell repertoire. Annu. Rev. Immunol. 20 (2002) 101-123
20. Lafaille J.J., Keere F.V.d., Hsu A.L., Baron J.L., Haas W., Raine C.S., and Tonegawa S. Myelin basic protein-specific T helper 2 (Th2) cells cause experimental autoimmune encephalomyelitis in immunodeficient hosts rather than protect them from the disease. J. Exp. Med. 186 (1997) 307-312
21. Lampasona V., Franciotta D., Furlan R., Zanaboni S., Fazio R., Bonifacio E., Comi G., and Martino G. Similar low frequency of anti-MOG IgG and IgM in MS patients and healthy subjects. Neurology 62 (2004) 2092-2094
22. Lassmann H., and Ransohoff R.M. The CD4-Th1 model for multiple sclerosis: a critical [correction of crucial] re-appraisal. Trends Immunol. 25 (2004) 132-137
23. Lefranc D., Almeras L., Dubucquoi S., de Seze J., Vermersch P., and Prin L. Distortion of the self-reactive IgG antibody repertoire in multiple sclerosis as a new diagnostic tool. J. Immunol. 172 (2004) 669-678
24. Liblau R.S., Singer S.M., and McDevitt H.O. Th1 and Th2 CD4+T cells in the pathogenesis of organ-specific autoimmune diseases. Immunol. Today 16 (1995) 34-38
25. Linthicum D.S. Development of acute autoimmune encephalomyelitis in mice: factors regulating the effector phase of the disease. Immunobiology 162 (1982) 211-220
26. Lionel A., de Seze J., Didier L., Sandrine F.N., Sylvain D., Patrick V., and Lionel P. Evolution of self-reactive IgG antibody repertoires in patients with relapsing-remitting multiple sclerosis. Immunol. Lett. 97 (2005) 55-62
27. Liu X.H., Eun B.L., and Barks J.D. Platelet-activating factor antagonist BN 50730 attenuates hypoxic-ischemic brain injury in neonatal rats. Pediatr. Res. 49 (2001) 804-811
28. Lock C., Hermans G., Pedotti R., Brendolan A., Schadt E., Garren H., Langer-Gould A., Strober S., Cannella B., Allard J., Klonowski P., Austin A., Lad N., Kaminski N., Galli S.J., Oksenberg J.R., Raine C.S., Heller R., and Steinman L. Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis. Nat. Med. 8 (2002) 500-508
29. Lyons J.A., San M., Happ M.P., and Cross A.H. B cells are critical to induction of experimental allergic encephalomyelitis by protein but not by a short encephalitogenic peptide. Eur. J. Immunol. 29 (1999) 3432-3439
30. Martin R., McFarland H.F., and McFarlin D.E. Immunological aspects of demyelinating diseases. Annu. Rev. Immunol. 10 (1992) 153-187
31. Mazer B., Clay K.L., Renz H., and Gelfand E.W. Platelet-activating factor enhances Ig production in B lymphoblastoid cell lines. J. Immunol. 145 (1990) 2602-2607
32. McLean B.N., Luxton R.W., and Thompson E.J. A study of immunoglobulin G in the cerebrospinal fluid of 1007 patients with suspected neurological disease using isoelectric focusing and the Log IgG-Index. A comparison and diagnostic applications. Brain 113 (1990) 1269-1289
33. McRae B.L., Kennedy M.K., Tan L.-J., Dal Canto M.C., Picha K.S., and Miller S.D. Induction of active and adoptive relapsing experimental autoimmune encephalomyelitis (EAE) using an encephalitogenic epitope of proteolipid protein. J. Neuroimmunol. 38 (1992) 229-240
34. Meinl E., Krumbholz M., and Hohlfeld R. B lineage cells in the inflammatory central nervous system environment: migration, maintenance, local antibody production, and therapeutic modulation. Ann. Neurol. 59 (2006) 880-892
35. Mendel I., Katz A., Kozak N., Ben-Nun A., and Revel M. Interleukin-6 functions in autoimmune encephalomyelitis: a study in gene-targeted mice. Eur. J. Immunol. 28 (1998) 1727-1737
36. Norgren N., Edelstam A., and Stigbrand T. Cerebrospinal fluid levels of neurofilament light in chronic experimental autoimmune encephalomyelitis. Brain Res. Bull. 67 (2005) 264-268
37. Panetta T., Marcheselli V.L., Braquet P., Spinnewyn B., and Bazan N.G. Effects of a platelet activating factor antagonist (BN 52021) on free fatty acids, diacylglycerols, polyphosphoinositides and blood flow in the gerbil brain: inhibition of ischemia-reperfusion induced cerebral injury. Biochem. Biophys. Res. Commun. 149 (1987) 580-587
38. Park T.S., Gonzales E.R., and Gidday J.M. Platelet-activating factor mediates ischemia-induced leukocyte-endothelial adherence in newborn pig brain. J. Cereb. Blood Flow Metab. 19 (1999) 417-424
39. Pedotti R., De Voss J.J., Steinman L., and Galli S.J. Involvement of both 'allergic' and 'autoimmune' mechanisms in EAE, MS and other autoimmune diseases. Trends Immunol. 24 (2003) 479-484
40. Pedotti R., DeVoss J.J., Youssef S., Mitchell D., Wedemeyer J., Madanat R., Garren H., Fontoura P., Tsai M., Galli S.J., Sobel R.A., and Steinman L. Multiple elements of the allergic arm of the immune response modulate autoimmune demyelination. Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 1867-1872
41. Petzold A. Neurofilament phosphoforms: Surrogate markers for axonal injury, degeneration and loss. J. Neurol. Sci. 233 (2005) 183-198
42. Qin Y., Duquette P., Zhang Y., Talbot P., Poole R., and Antel J. Clonal expansion and somatic hypermutation of V(H) genes of B cells from cerebrospinal fluid in multiple sclerosis. J. Clin. Invest. 102 (1998) 1045-1050
43. Rozniecki J.J., Hauser S.L., Stein M., Lincoln R., and Theoharides T.C. Elevated mast cell tryptase in cerebrospinal fluid of multiple sclerosis patients. Ann. Neurol. 37 (1995) 63
44. Secor V.H., Secor W.E., Gutekunst C.A., and Brown M.A. Mast cells are essential for early onset and severe disease in a murine model of multiple sclerosis. J. Exp. Med. 191 (2000) 813-822
45. Steinman L. Multiple sclerosis: a coordinated immunological attack against myelin in the central nervous system. Cell 85 (1996) 299-302
46. Storch M.K., Piddlesden S., Haltia M., Iivanainen M., Morgan P., and Lassmann H. Multiple sclerosis: in situ evidence for antibody- and complement-mediated demyelination. Ann. Neurol. 43 (1998) 465-471
47. Tanzola M.B., Robbie-Ryan M., Gutekunst C.A., and Brown M.A. Mast cells exert effects outside the central nervous system to influence experimental allergic encephalomyelitis disease course. J. Immunol. 171 (2003) 4385-4391
48. Theoharides T.C. Mast cells: the immune gate to the brain. Life Sci. 46 (1990) 607-617
49. Theoharides T.C., and Cochrane D.E. Critical role of mast cells in inflammatory diseases and the effect of acute stress. J. Neuroimmunol. 146 (2004) 1
50. Trapp B.D., Peterson J., Ransohoff R.M., Rudick R., Mork S., and Bo L. Axonal transection in the lesions of multiple sclerosis. N. Engl. J. Med. 338 (1998) 278-285
51. Tuomisto L., Kilpelainen H., and Riekkinen P. Histamine and histamine-N-methyltransferase in the CSF of patients with multiple sclerosis. Agents Actions 13 (1983) 255
52. Uccelli A., Aloisi F., and Pistoia V. Unveiling the enigma of the CNS as a B-cell fostering environment. Trends Immunol. 26 (2005) 254-259
53. Vela L., Garcia Merino A., Fernandez-Gallardo S., Sanchez Crespo M., Lopez Lozano J.J., and Saus C. Platelet-activating factor antagonists do not protect against the development of experimental autoimmune encephalomyelitis. J. Neuroimmunol. 33 (1991) 81-86
54. Wolf S.D., Dittel B.N., Hardardottir F., and Janeway Jr. C.A. Experimental autoimmune encephalomyelitis induction in genetically B cell-deficient mice. J. Exp. Med. 184 (1996) 2271-2278
55. Wucherpfennig K.W., Catz I., Hausmann S., Strominger J.L., Steinman L., and Warren K.G. Recognition of the immunodominant myelin basic protein peptide by autoantibodies and HLA-DR2-restricted T cell clones from multiple sclerosis patients. Identity of key contact residues in the B-cell and T-cell epitopes. J. Clin. Invest. 100 (1997) 1114-1122
56. Zephir H., Almeras L., El Behi M., Dussart P., de Seze J., Steibel J., Trifilieff E., Dubucquoi S., Dessaint J.-P., and Vermersch P. Diversified serum IgG response involving non-myelin CNS proteins during experimental autoimmune encephalomyelitis. J. Neuroimmunol. 179 (2006) 53-64
57. Ziemssen T., and Ziemssen F. The role of the humoral immune system in multiple sclerosis (MS) and its animal model experimental autoimmune encephalomyelitis (EAE). Autoimmun. Rev. 4 (2005) 460-467